Drug Discovery

Innovac raises funding for lead programmes development

Innovac Therapeutics has raised $18m in Series Pre-A financing for funding the development of its lead programmes and manufacturing capabilities.

Allucent to expedite Covid-19 booster vaccines development

Allucent has received a contract from the Biomedical Advanced Research and Development Authority (BARDA) to expedite clinical research and development of next-generation booster vaccines for Covid-19.

Daiichi Sankyo to close Japanese research and development subsidiary

Daiichi Sankyo has announced its decision to shut down its Japanese research and development (R&D) subsidiary to further strengthen its capabilities.

Solu Therapeutics raises funds to develop CyTaC platform and drug candidates

Precision-medicine company Solu Therapeutics has raised $31m in seed financing to develop the Cytotoxicity Targeting Chimera (CyTaC) platform and drug candidates.

Viatris, Kindeva launch Breyna to treat asthma and COPD patients

Viatris and Kindeva Drug Delivery have launched Breyna (budesonide and formoterol fumarate dihydrate) Inhalation Aerosol to treat certain asthma and chronic obstructive pulmonary disease (COPD) patients.

NMPA accepts Overland ADCT BioPharma’s BLA for ZYNLONTA

The China National Medical Products Administration (NMPA) has accepted and granted priority review to Overland ADCT BioPharma’s biologics license application (BLA) for ZYNLONTA (loncastuximab tesirine-lpyl).

Sandoz launches action plan to improve access to biosimilar medicines

Generic and biosimilar medicines provider Sandoz has introduced a global action plan to provide patients with quick access to biologic medicines.

Fresenius Kabi introduces Vasopressin Injection, USP, in US

A global health care company Fresenius Kabi has announced the availability of Vasopressin injection, USP, in the US for treating adults with vasodilatory shock.

Charles River Laboratories, Curigin partner on gene therapy

Charles River Laboratories International has teamed up with Korean biotechnology company Curigin for producing oncolytic ribonucleic acid interference (RNAi) gene therapy.